Amid a stream of largely bleak forecasts that biopharmas will continue to shed jobs in coming years, GEN offered some glimmers of hope a few months back, in the form of 10 research and clinical biotech occupations projected to add jobs through 2022, according to the U.S. Bureau of Labor Statistics (BLS) Occupational Outlook Handbook, 2014-15 Edition.
This week, GEN looks further at promising biopharma jobs by offering a list of 10 occupations for which numerous positions remain unfilled, based on visits to the career sections of websites for 10 biopharma companies between Nov. 7-12. The 10 companies visited were: Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi.
The 10 occupations include positions in R&D, as well as manufacturing, and administrative jobs. The positions reflect the growing importance of data, translational medicine, and payer reimbursement as key factors in biopharma, in addition to traditional science and business know-how.